M R Wright
Overview
Explore the profile of M R Wright including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
250
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wright M
J Youth Adolesc
. 2013 Nov;
18(1):71-83.
PMID: 24271605
In a longitudinal developmental study, 90 girls and boys participated in a psychological investigation, and were medically examined when they were 11, 13, 15, and 18 years old. Their satisfaction...
2.
3.
4.
Ray A, Wright M, Rhodes G
Clin Pharmacol Ther
. 2008 Jul;
84(6):660.
PMID: 18615003
No abstract available.
5.
Wong H, Grace Jr J, Wright M, Browning M, Grossman S, Bai S, et al.
Xenobiotica
. 2006 Dec;
36(12):1178-90.
PMID: 17162465
The chimpanzee has recently been characterized as a surrogate for oxidative drug metabolism in humans and as a pharmacokinetic model for the selection of drug candidates. In the current study,...
6.
Pinto D, Orwat M, Wang S, Fevig J, Quan M, Amparo E, et al.
J Med Chem
. 2001 Feb;
44(4):566-78.
PMID: 11170646
Factor Xa (fXa) plays a critical role in the coagulation cascade, serving as the point of convergence of the intrinsic and extrinsic pathways. Together with nonenzymatic cofactor Va and Ca2+...
7.
Wong P, Crain E, Knabb R, Meade R, Quan M, Watson C, et al.
J Pharmacol Exp Ther
. 2000 Sep;
295(1):212-8.
PMID: 10991981
SK549 (mol. wt. 546 Da) is a synthetic, selective inhibitor of human coagulation factor Xa (fXa) (K(i) = 0.52 nM). This study compared the antithrombotic effects of SK549 and a...
8.
Pruitt J, Pinto D, Estrella M, Bostrom L, Knabb R, Wong P, et al.
Bioorg Med Chem Lett
. 2000 Apr;
10(8):685-9.
PMID: 10782664
3,4,5-Trisubstituted isoxazolines (2) and isoxazoles (3) were prepared and evaluated for their in vitro and in vivo antithrombotic efficacy. They were compared to 3,5,5-trisubstituted isoxazolines (1) for Factor Xa selectivity...
9.
Galemmo Jr R, Wells B, Rossi K, ALEXANDER R, Dominguez C, Maduskuie T, et al.
Bioorg Med Chem Lett
. 2000 Mar;
10(3):301-4.
PMID: 10698459
In this report refinements to the S4 ligand group leads to compound 19, an inhibitor of fXa with good potency in vitro and an improved pharmacokinetic profile in rabbit. The...
10.
Quan M, ELLIS C, Liauw A, ALEXANDER R, Knabb R, Lam G, et al.
J Med Chem
. 1999 Jul;
42(15):2760-73.
PMID: 10425087
Intravascular clot formation is an important factor in a number of cardiovascular diseases. Therefore, the prevention of blood coagulation has become a major target for new therapeutic agents. One attractive...